Clinical-stage biopharmaceutical company Alzheon has secured $100m in a Series E funding round to develop and commercialise ALZ-801/Valiltramiprosate, an oral tablet designed as a disease-modifying therapy for Alzheimer’s disease (AD). Alerce Medical Technology Partners spearheaded the financing round. The gold standard of business intelligence.
The development comes after the company raised $50m in a Series D round in 2022. The investment will be used to complete the APOLLOE4 Phase III clinical trial to evaluate the efficacy of ALZ-801 in 325 early AD patients. The study will report its results in the third quarter of 2024, with a new drug application (NDA) submission to follow.
ALZ-801 inhibits the formation of soluble toxic amyloid aggregates, acting upstream from all late-stage amyloid-targeting treatments. Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research.
Gain competitive edge. Your download email will arrive shortly We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form The financial boost will also support the manufacture of the product and prepare for the potential launch of ALZ-801 commercially, as the first oral disease-modifying therapy for Alzheimer’s.
ALZ-801 has demonstrated the ability to fully block the formation of neurotoxic soluble .